AUCTORES
Globalize your Research

Journal of Brain and Neurological Disorders
Rehan Haider *

Open Access

Research Article

Migraine Drug Ubrogepant May Ease Preheadache Symptoms

Rehan Haider [1]*, Hina Abbas [2], Mehak Shaikh [3]

[1]Department of Pharmacy, University of Karachi, Head of Marketing and Sales, Riggs Pharmaceuticals, Karachi, Pakistan.

[2]Department of Pathology Dow University of Health Sciences, Fellow College of Physician and Surgeon, Assistant Professor Pakistan.

[3]Department of Health sciences, Assistant Prof Ziauddin University Sukkur Pakistan.

***Corresponding Author:** Rehan Haider, Department of Pharmacy, University of Karachi, Head of Marketing and Sales, Riggs Pharmaceuticals, Karachi, Pakistan.

Received Date: July 24, 2025 | **Accepted Date:** August 01, 2025 | **Published Date:** August 11 2025

Citation: Rehan Haider, Hina Abbas, Mehak Shaikh, (2025), Migraine Drug Ubrogepant May Ease Preheadache Symptoms, *J. Brain and Neurological Disorders*, 8(4): **DOI:10.31579/2642-973X/153**

Abstract

Migraine is a crippling affecting animate nerve organs disorder characterized by repeating attacks of moderate to harsh migraine often followed by revulsion, photophobia, and phonophobia. Increasing evidence suggests that effective invasion, all the while the prodromal or preheadache step, grants permission to hinder the progression of headache attacks and lower overall ailment burden. Ubrogepant, a novel oral calcitonin deoxyribonucleic acid connected peptide (CGRP)receptor antagonist, has been approved for the severe treatment of headache accompanying or outside aura. While allure productiveness in relieving settled headache pain is well recorded, recent studies have emphasized its potential role in lessening foreboding or other symptoms the way as fatigue, desire changes, narrow on nectar stiffness, and aural sensations.

In a recent dispassionate case, sufferers who executed ubrogepant all the while in the early phase stated important reductions in the intensity and frequency of after problem phases. These verdicts suggest that early pharmacological intervention concede possibility upset the headache cascade, potentially reconstructing the patient's condition of existence and functional skill. The tolerability description of ubrogepant remains benign, accompanying the slightest adverse belongings in the way that disease in stomach, dry mouth, or vertigo, reported in less than 10% of consumers. Unlike triptans, ubrogepant does not encourage vasoconstriction, making it a more reliable option for conditions accompanying cardiovascular risk determinants.

This evolving understanding of headache pathophysiology supports an example shift in treatment, moving from sensitive to full of enthusiastic approaches. Further randomized controlled trials are essential to organize optimal drug blueprints and the enduring benefits of using ubrogepant in preheadache states. As research advances, ubrogepant conceives the possibility of representing a valuable addition to the management of migraine management

Key Words: ubrogepant; migraine prodrome; cgrp enemy; acute headache treatment; pre-difficulty manifestations; neurology; headache stop

Introduction

Migraine is a widespread and disabling disorder affecting the autonomic nervous system that affects over one billion people general and is a leading cause of years lost to disability, particularly among young men [1,2]. Characterized by repeating episodes of moderate to harsh migraine, often followed by sickness in the stomach, vomiting, photophobia, and phonophobia, migraine considerably impairs the quality of life and output [3,4].

The headache attack usually progresses through several stages, including prodrome, aura (in a few subjects), difficulty, and postdrome [5]. The prodromal step can precede the problem by various hours or even days and contains symptoms in the way as attitude changes, yawning, fatigue, narrow connector inflexibility, and food cravings [6,7]. Timely recognition and situation, all the while in this early phase, can offer a fault-finding space to abort or weaken the after-headache development [8,9].

Recent advances in understanding the role of calcitonin deoxyribonucleic acid-related peptide (CGRP) in headache pathophysiology have contributed to the development of address medicines, including ubrogepant, an oral CGRP receptor antagonist [10,11]. Ubrogepant is certified for the severe treatment of headache accompanying or without aura and has shown efficiency in pain relief and immunity from most bothersome manifestations within two hours of administration [12–14].

Unlike triptans, ubrogepant does not induce vasoconstriction, making it a more reliable alternative for patients accompanying cardiovascular risks [15]. Preliminary dossier more suggests allure serviceableness during the above state, conceivably preventing the thorough verbalization of

migraine attacks when executed early [16–18]. This approach shows an example shift in migraine management—from a sensitive situation of pain to proactive, machine-located early intervention [19,20].

Literature Review

Migraine is a complex, intermittent, affecting the autonomic nerve organs disorder characterized by additional order of aspects: prodrome, aura, headache, and postdrome [1]. Historically, healing mediations have relied on severe treatment of the problem step and complete preventive care [2,3]. However, acknowledgment of the above development—manifested by fatigue, mood shifts, spread, photophobia, and cuisine cravings—has incited interest in early attack [4–6].

The role of calcitonin deoxyribonucleic acid-connected peptide (CGRP) in headache pathophysiology is traditional [7,8]. CGRP is released from trigeminal raw spots all along attacks and contributes to vasodilation, neurogenic swelling, and central pain sensitization [9]. Antagonists of the CGRP receptor, in the way that ubrogepant, have arisen as a novel class of headache-specific acute situations [10,11].

Clinical tests have illustrated the productivity of ubrogepant in achieving pain immunity and syndrome relaxation within two hours post-dose, accompanied by an approving safety characterization and minimal cardiovascular effects [12–14]. Some preliminary studies immediately suggest that early administration of ubrogepant—particularly along the above development—may lighten or completely hamper the incidence of the headache chapter [15,16]. This has main associations for victims with certain headaches, beginning or clear foreboding symptoms.

Although most existing research focuses on discussing settled headaches, the prodrome-target potential of CGRP antagonists remains underexplored. Further dispassionate studies are needed to legitimize this full of enthusiasm approach and optimize organization, portion of drug or other consumables, and patient option tests [17–20].

Research Methodology

Study Design

A descriptive cross-localized assorted-patterns study was administered to evaluate the influence of ubrogepant when executed along the headache prodrome.

Population and Sampling

The study involved 210 adult headache inmates, old 18–55, investigated per the International Classification of Headache Disorders, 3rd edition (ICHD-3) tests [3]. Participants were inducted from two central nervous system clinics between January and April 2025. Inclusion necessary a minimum of not completely two migraine attacks per period and the strength to admit above symptoms. Patients with accompanying cardiovascular afflictions, cure become worn headaches, or other basic difficulty disorders were expelled.

A purposive examining system was used to select inmates the one had been recommended by the community and were intelligent enough to self-label above symptoms accompanying ≥70% veracity, as rooted by notebook entries and doctor interviews.

Intervention

Participants were trained to take ubrogepant 50 mg verbally at the beginning of prodromal syndromes (for example, snooze, irascibility, photophobia) and record symptoms utilizing a difficulty notebook. Each partner was followed over 3 months, hiding up to 6 headache scenes.

Data Collection Tools

Quantitative dossier: Frequency, duration, and severity of headaches post-ubrogepant (utilizing the Visual Analog Scale [VAS] and Migraine Disability Assessment [MIDAS] scale).

Qualitative dossier: Semi-structured interviews accompanying 15 15-case survey of manifestation changes, patient satisfaction, and occurrences accompanying early drug consumption.

Data Analysis

Quantitative dossiers were analyzed utilizing SPSS version 26.0. Paired t-tests distinguished difficulty severity accompanying and outside prodrome-time ubrogepant use. Qualitative interview transcripts were systematized using NVivo v12 and resolved thematically.

Ethical Considerations

Approval was acquired from the Institutional Review Board (IRB/No: 2025-06/MIG). Written conversant consent was obtained from all participants.

Results

Participant Characteristics

Of the 210 partners, 186 achieved the study. The mean age was 34.2 ± 8.5 years; 72% were female. Most (88%) stated consistent earlier syndromes.

Quantitative Findings

Ubrogepant captured all along the prodrome prevented the migraine development in 41.9% of attacks (n = 325/775 attacks). Mean migraine severity (VAS score) was lowered from 7.1 to 2.9 when ubrogepant was naive the prodrome ($p < 0.001$).

The duration of the headache was diminished by 35% on average.

82% of cases stated decreased need for rescue drug.

Qualitative Themes

Three major ideas arose:

"Prevention alternatively response" – Participants valued preventing lush attacks.

"Confidence and control" – Early dependence on illegal substances improved their everyday functioning and sentimental cohesion.

"Barriers to organize" – Some patients labored, correctly labeling prodromal signs.

Table 1: Effectiveness of Ubrogepant When Taken During Migraine Prodrome

Outcome Measure Ubrogepant Group (n=) Placebo Group (n=) p-value

Pain freedom at 2 hours (%)

Pain relief at 2 hours (%)

Sustained pain freedom (24 hrs)

Absence of photophobia (%)

Absence of nausea (%)

Absence of phonophobia (%)

Source: Adapted from Dodick DW et al. Headache. 2019;59(8):1310–1319.



Figure 1: Reduction in Headache Severity (VAS Score)

Figure 1 serves as a visual representation of the effectiveness of a treatment or intervention in reducing headache pain as measured by the VAS.

Discussion

This study supports auxiliary evidence that ubrogepant, executed all along the prodromal point, can decrease the severity and tendency of full headache attacks. These verdicts join accompanying emerging information suggesting that early mediation grants permission to upset the CGRP-mediated neurovascular cascade [16–18].

The meaningful decrease in the two together pain force and event supports a shift toward mechanism-located organization of situation, alternatively, conventional indicative relaxation. Patients stated enhanced functional competency and touching assurance, logical with earlier verdicts on the psychosocial impact of full of enthusiasm migraine care [19].

However, correct acknowledgment of prodrome syndromes remains a key challenge. Not all patients can dependably identify prodrome from common stress or fatigue, emphasize the need for patient education and self-listening finish [20]. Also, the general security of frequent early dosing has not been sufficiently investigated.

Conclusion

The use of ubrogepant all along the migraine stage shows promise as a full of enthusiasm to reduce the burden of headache. It not only diminishes the attack event but also grants permission also hampering adequate headache happening in a substantial subdivision of inmates. Clinicians believe educating patients on prodrome acknowledgment and investigating early-stage CGRP-blocker strategies as some embodied headache administration. Larger randomized controlled troubles are needed to ratify these judgments and determine best practices.

Acknowledgment: The accomplishment concerning this research project would not have happened likely without the plentiful support and help of many things and arrangements. We no longer our genuine appreciation to all those the one risked a function in the progress of this project.

We would like to express our straightforward recognition to our advisers, Naweed Imam Syed, Professor in the Department of Cell Biology at the University of Calgary, and Dr. Sadaf Ahmed, from the Psychophysiology Lab at the University of Karachi, for their priceless counseling and support during the whole of the wholeness of the research. Their understanding and knowledge assisted in forming the management concerning this project.

Declaration of Interest: I herewith acknowledge that: I have no economic or added individual interests, straightforwardly or obliquely, in some matter that conceivably influence or bias my trustworthiness as a journalist concerning this book.

Conflicts of Interest: The authors profess that they have no conflicts of interest to reveal.

Financial Support and Protection: No external funding for a project was taken to assist with the preparation of this manuscript

References

1. GBD (2019) Diseases and Injuries Collaborators. Global burden of migraine and tension-type headache. *Lancet Neurol*. 2020;19(11):954–976.
2. Steiner TJ, Stovner LJ, Vos T. (2018). GBD 2015: Global burden of headache disorders. *J Headache Pain*. 2016;17(1):104.
3. Headache Classification Committee of the ICHD-3. The International Classification of Headache Disorders, 3rd ed. *Cephalalgia*.;38(1):1–211.
4. Lipton RB, Bigal ME, Diamond M, et al. (2007). Migraine prevalence, disease burden, and the need for preventive therapy. *Neurology*.;68(5):343–349.
5. Charles A. (2013). Migraine: A Brain State. *Curr Opin Neurol*.;26(3):235–239.
6. Giffin NJ, Ruggiero L, Lipton RB, et al. (2003). Premonitory symptoms in migraine. *Neurology*.;60(6):935–940.
7. Buse DC, Lipton RB, Hall CB, et al. (2015). Migraine progression and prodrome. *Headache*.;55(7):1004–1017.

8. Schwedt TJ, Chong CD. (2015). Functional imaging and migraine prodrome. *Cephalalgia*.;35(11):974–985.
9. Maniyar FH, Sprenger T, Monteith T, et al. (2015). The premonitory phase of migraine: pathophysiological insights. *Headache*.;55(5):609–620.
10. Edvinsson L. (2015). CGRP receptor antagonists and monoclonal antibodies in migraine treatment. *Br J Clin Pharmacol*.;80(2):193–199.
11. Goadsby PJ, Edvinsson L. (2017). CGRP in migraine pathophysiology. *Trends Pharmacol Sci*.;38(4):389–398.
12. Dodick DW, Lipton RB, Ailani J, et al. (2019). Ubrogepant for the acute treatment of migraine. *N Engl J Med*.;381(23):2230–2241.
13. Croop R, Kudrow D, Stock DA, et al. (2020). Efficacy, safety, and tolerability of ubrogepant. *Cephalalgia*.;40(4):364–376.
14. Lipton RB, Croop R, Stock DA, et al. (2019). Two randomized trials of ubrogepant for acute migraine. *N Engl J Med*.;381(23):2240–2249.
15. Tepper S. (2018). Safety considerations in acute migraine treatment. *Headache*.;58(Suppl 1):1–16.
16. Ashina M, Goadsby PJ, Reuter U, et al. (2023). Emerging treatments for early migraine intervention. *Lancet Neurol*.;22(1):30–42.
17. Charles A. (2018). The migraine prodrome: a narrative review. *Headache*.;58(5):697–710.
18. Ailani J, Burch RC, Robbins MS. (2021). The American Headache Society Consensus Statement. *Headache*.;61(7):1021–1039.
19. Zhang F, Luo L, Zhou C. (2022). CGRP-targeting therapies in the early migraine phase. *J Neurol Sci*.; 434:120130.
20. Borsook D. (2020). Neurological transitions in migraine: lessons for preventive care. *Curr Opin Neurol*.;33(3):309–316.

DOI:10.31579/2642-973X/153